CN101340910B - 抗药性肿瘤的治疗 - Google Patents

抗药性肿瘤的治疗 Download PDF

Info

Publication number
CN101340910B
CN101340910B CN2006800482417A CN200680048241A CN101340910B CN 101340910 B CN101340910 B CN 101340910B CN 2006800482417 A CN2006800482417 A CN 2006800482417A CN 200680048241 A CN200680048241 A CN 200680048241A CN 101340910 B CN101340910 B CN 101340910B
Authority
CN
China
Prior art keywords
drug
treatment
topoisomerase
tumor
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800482417A
Other languages
English (en)
Chinese (zh)
Other versions
CN101340910A (zh
Inventor
C·皮萨诺
L·维西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101340910A publication Critical patent/CN101340910A/zh
Application granted granted Critical
Publication of CN101340910B publication Critical patent/CN101340910B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
CN2006800482417A 2005-12-21 2006-12-13 抗药性肿瘤的治疗 Expired - Fee Related CN101340910B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027997.5 2005-12-21
EP05027997 2005-12-21
PCT/EP2006/069666 WO2007071603A1 (en) 2005-12-21 2006-12-13 Treatment of drug-resistant tumors

Publications (2)

Publication Number Publication Date
CN101340910A CN101340910A (zh) 2009-01-07
CN101340910B true CN101340910B (zh) 2012-12-12

Family

ID=35911064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800482417A Expired - Fee Related CN101340910B (zh) 2005-12-21 2006-12-13 抗药性肿瘤的治疗

Country Status (19)

Country Link
US (1) US7888368B2 (enExample)
EP (1) EP1962850B1 (enExample)
JP (1) JP5657205B2 (enExample)
KR (1) KR101366868B1 (enExample)
CN (1) CN101340910B (enExample)
AT (1) ATE548038T1 (enExample)
AU (1) AU2006328607B2 (enExample)
BR (1) BRPI0620209A2 (enExample)
CA (1) CA2631868C (enExample)
CY (1) CY1112814T1 (enExample)
DK (1) DK1962850T3 (enExample)
EA (1) EA016487B1 (enExample)
ES (1) ES2382819T3 (enExample)
HR (1) HRP20120359T1 (enExample)
PL (1) PL1962850T3 (enExample)
PT (1) PT1962850E (enExample)
RS (1) RS52272B (enExample)
SI (1) SI1962850T1 (enExample)
WO (1) WO2007071603A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
JP5765937B2 (ja) * 2007-08-01 2015-08-19 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 小児腫瘍の治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044977A1 (en) * 1999-03-09 2000-10-18 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044977A1 (en) * 1999-03-09 2000-10-18 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity

Also Published As

Publication number Publication date
CN101340910A (zh) 2009-01-07
EP1962850A1 (en) 2008-09-03
HRP20120359T1 (hr) 2012-06-30
JP2009520754A (ja) 2009-05-28
WO2007071603A1 (en) 2007-06-28
DK1962850T3 (da) 2012-06-18
ES2382819T3 (es) 2012-06-13
EA016487B1 (ru) 2012-05-30
US7888368B2 (en) 2011-02-15
PL1962850T3 (pl) 2012-07-31
AU2006328607A1 (en) 2007-06-28
CA2631868C (en) 2014-02-11
HK1124776A1 (zh) 2009-07-24
CA2631868A1 (en) 2007-06-28
BRPI0620209A2 (pt) 2011-11-01
PT1962850E (pt) 2012-05-21
ATE548038T1 (de) 2012-03-15
AU2006328607B2 (en) 2012-04-19
JP5657205B2 (ja) 2015-01-21
EP1962850B1 (en) 2012-03-07
CY1112814T1 (el) 2016-02-10
EA200870073A1 (ru) 2009-12-30
RS52272B (sr) 2012-10-31
KR101366868B1 (ko) 2014-02-21
KR20080078055A (ko) 2008-08-26
SI1962850T1 (sl) 2012-06-29
US20080312265A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
JPH01186893A (ja) 水溶性カンプトテシン類似体
TW202023563A (zh) 新穎喹唑啉egfr抑制劑
US20130225610A1 (en) Antimetastatic compounds
CN1774253A (zh) 用环氧丙酯酮衍生物治疗顽固性肿瘤
Kawato et al. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats
US20110262383A1 (en) Naphthalimide Dosing by N-Acetyl Transferase Genotyping
CN101340910B (zh) 抗药性肿瘤的治疗
US8344017B2 (en) Anti-hepatitis C virus agents and anti-HIV agents
US20030149088A1 (en) HIV treatment
US8853233B2 (en) Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
TWI472330B (zh) 用於癌症治療之增敏劑、套組及用途
HK1124776B (en) Treatment of drug-resistant tumors
Yount et al. A novel camptothecin analog with enhanced antitumor activity
JP2002540149A (ja) ウイルス感染治療のためのカルバミン酸エステル誘導体の使用法
US20050288310A1 (en) Methods of treating cellular proliferative disease using naphthalimide and PARP-1 inhibitors
SK397391A3 (sk) 9,10-Substituované kamptotecíny, farmaceutický prípravok s ich obsahom a medziprodukt
WO2009104150A1 (en) Combination comprising bosentan for treating ovarian cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124776

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1124776

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121212

Termination date: 20161213

CF01 Termination of patent right due to non-payment of annual fee